Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant

On Aug 17, 2023, WHO designated BA.2.86 as a variant under monitoring.3 We first estimated the effective reproduction number (Re) of BA.2.86 based on genome surveillance data until Sept 4, 2023, in Denmark, where multiple XBB subvariants including EG.5.1 are currently co-circulating, and 12 BA.2.86...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2023-11, Vol.23 (11), p.e460-e461
Main Authors: Uriu, Keiya, Ito, Jumpei, Kosugi, Yusuke, Tanaka, Yuri L, Mugita, Yuka, Guo, Ziyi, Hinay, Alfredo A, Putri, Olivia, Kim, Yoonjin, Shimizu, Ryo, Begum, MST Monira, Jonathan, Michael, Saito, Akatsuki, Ikeda, Terumasa, Sato, Kei
Format: Article
Language:English
Subjects:
Cell culture
Consortia
Genomes
Immune evasion
Infectious diseases
Infectivity
Medical research
Mutation
Pharmaceuticals
R&D
Research & development
Severe acute respiratory syndrome coronavirus 2
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On Aug 17, 2023, WHO designated BA.2.86 as a variant under monitoring.3 We first estimated the effective reproduction number (Re) of BA.2.86 based on genome surveillance data until Sept 4, 2023, in Denmark, where multiple XBB subvariants including EG.5.1 are currently co-circulating, and 12 BA.2.86 sequences were reported (appendix p 10). The fact that the lower infectivity of BA.2.86 does not translate into its lower Re is reminiscent of the findings for omicron BA.1 and BA.2: although BA.1 and BA.2 are less infectious than other variants such as delta in cell culture, these omicron variants exhibited greater immune escape capacity.4,5 These observations suggest that Re can be determined by multiple factors such as infectivity and immune evasive potential. [...]a neutralisation assay using XBB breakthrough infection sera showed that the 50% neutralisation titre of XBB breakthrough infection sera against BA.2.86 was significantly (1·6-fold) lower than that against EG.5.1 (p
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(23)00575-3